The Intersection of Applied Behavior Analysis and Behavioral Pharmacology Tom Byrne, Ph.D., BCBA-D MCLA





"Drug use is so entrenched in our society that anyone interested in human behavior must consider its influence." (Higgins, Hughes, & Gallager, 1987)

# We practice the science of behavior change.

- Drugs can have profound effects on behavior.
- Behavior analysts may not receive specific training in the behavioral effects of drugs.
- Some of your clients are/will be prescribed psychoactive drugs.
- Estimates of the percentage of children diagnosed with autism and receiving pharmacotherapy range from 30 to 42 percent (Sullivan and Sadeh, 2014)
- Estimates of the percentage of children diagnosed with ADHD and receiving pharmacotherapy fall between 40 and 69 percent. (CDC, 2011)

#### Two assertions

- It would be beneficial for behavior analysts to be conversant regarding those psychoactive medications we encounter frequently.
- Our training and methodology places us in a good position to evaluate drug effects.

# The FDA has approved two drugs for autism treatment

- Risperidone (Risperdal)
- Aripiprozole (Abilify)
- Both are atypical or second-generation antipsychotics
- Behavior analysts may be unfamiliar and perhaps, surprised, with the research methodology used in clinical drug trials.

### Risperidone in Children with Autism and Serious Behavioral Problems

New England Journal of Medicine (2002)

James T. McCracken, James McGough, Bhavik Shah,  $\bullet$ Pegeen Cronin, Daniel Hong, Michael G. Aman, L. Eugene Arnold, Ronald Lindsay, Patricia Nash, Jill Hollway, Christopher J. McDougle, David Posey, Naomi Swiezy, Arlene Kohn, Lawrence Scahill, Andres Martin, Kathleen Koenig, Fred Volkmar, Deirdre Carroll, Allison Lancor, Elaine Tierney, Jaswinder Ghuman, Nilda M. Gonzalez, Marco Grados, Benedetto Vitiello, Louise Ritz, Mark Davies, James Robinson, and Don McMahon, M.S.

### From the Abstract

#### Conclusions

"Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia. (p. 315)"

### Data



### Irritability?

- Tantrums, aggression, and self-injurious behavior were viewed in a topographical rather than a functional context.
- IMHO, they were treated more like an infection.
- Behavior was not measured directly.

### ABC's were used

#### Antecedent Behavior Consequence?

No

#### Aberrant Behavior Checklist

### **Aberrant Behavior Checklist**

- ABC includes an "Irritability" subscale
- "Please rate the child's behavior according to the scale below:
  - 0 = behavior is not a problem
  - 1 = The behavior is a slight problem
  - 2 = The behavior is a moderate problem
  - 3 = The behavior is a severe problem

### ABC continued

- Self injury
- Tantrums
- Crying and screaming
- "Irritable and Whiny"

### Fast and easy

### Side Effects (p <.05)

- Increased appetite
- Fatigue
- Drowsiness
- Drooling
- Weight gain (mean of 2.7 kg in 8 weeks)

#### A note regarding placebo control

### Influence: Cited over 500 times

#### • Impact Factor:



The NEW ENGLAND JOURNAL of MEDICINE

# 54.42



1.087

A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder

Journal of the American Academy of Child and Adolescent Psychiatry (2009)

(I will list the authors later)

### Again, from the abstract

"Aripiprazole was efficacious and generally safe and well tolerated in the treatment of children and adolescents with irritability associated with autistic disorder."

### Main DV?

"At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores"

# Authors and Affiliations

Author	Affiliation
R.N. Marcus	Bristol-Myers Squibb
R. Owen	Bristol-Myers Squibb
L. Kamen	Bristol-Myers Squibb
G. Manos	Bristol-Myers Squibb
R.D. McQuade	Otsuka Pharmaceutical Co
W.H. Carson	Otsuka Pharmaceutical Co
M. Aman	Ohio State University

A metaphor: intervention for reducing automobile accidents

Prior to designing intervention, we should examine why accidents happen:

Driver impairment (drugs, sleep, texting)

Weather (ice, glare)

Mechanical failure (faulty brakes, blowouts)

Driver experience

Animal crossings

### Never mind!

- Too much trouble! Let's just lump it all together and call it . . .
- Crashability
- Intervention will involve setting speed governors at 10 mph.
- Data: Let's not bother with actually counting accidents.

## UCLC (Unusual Car Condition Checklist)

- Please rate your car's condition for the past four weeks. For each item assign the appropriate number:
  - 0 = Not a problem
  - 1 = A little problem
  - 2 = A moderate problem
  - 3 = A severe problem

### **Crashability Subscale**

- Seek frequent contact with large objects.
- Accelerate at inappropriate times
- Unresponsive to pedestrians
- Make lane changes quickly and unpredictably

### Some Historical Notes

- Johnson & Johnson Ordered to Pay More Than \$2.2 Billion to Resolve Criminal and Civil Investigations (Department of Justice, 2013)
- Note that J&J sold \$4.5 billion of Risperidone in 2007 alone
- Current lawsuits (hundreds) regarding gynacomastia. One recent settlement involved a young man who developed size 44DD breasts.

When it comes to assessing drug effects, you can do better

- As behavior analysts, we are in a good place to

   a) measure behavior, b) evaluate treatment
   efficacy and c) identify stimulus function.
- With some study, these skills can be applied to investigating drug effects.

### **Behavioral Pharmacology**

- Essentially a merger of behavior analysis and pharmacology
- If you have formal training in behavior analysis, you already understand much of the approach

# Stimulus Functions of Drugs

Α	В	С
discriminative stimuli motivational operations unconditioned stimuli conditioned stimuli		reinforcers punishers

# Stimulus Functions of Drugs

Α	В	С
discriminative stimuli <b>motivational operations</b> unconditioned stimuli conditioned stimuli		reinforcers punishers

### **Drugs as Motivational Operations**

 A drug functions as a motivational operation if it alters the reinforcing efficacy of other stimuli. Methylphenidate increases cigarette smoking in participants with ADHD.

• Psychopharmacology (2011)

 Vansickel, A.R., Stoops, W.W., Glaser, P.E.A., Poole, M.M., & Rush, C.R.



Fig. 1 Dose-response functions for total number of puffs (top panel) and carbon monoxide levels (bottom panel). X-axes methylphenidate dose in milligrams; data points above PL designate placebo values. Data points show the means of nine participants. Filled symbols indicate those values that are significantly different from the placebo value



Fig. 2 Dose-response functions for number of food items (*top panel*) and calories consumed (*bottom panel*). All other details are the same as for Fig. 1

An Evaluation of Methylphenidate as a Potential Establishing Operation for Some Common Classroom Reinforcers

Journal of Applied Behavior Analysis (1998)

Northup, J., Fusilier, I. Swanson, V., Roane, H., and Borrero, J.



Use of Functional Analysis Methodology in the Evaluation of Medication Effects

Journal of Autism and Developmental Disorders (2003)

Crosland, K.A, Zarcone, J.R., Lindauer, S.E., Valdovinos, M.G., Zarcone, T.J., Hellings, J.A., & Schroder, S.R.



### Back where we started

**Could medication change cause an increase in maladaptive behavior?** 



- AO: Reduce reinforcing efficacy of contrived reinforcers.
- MO: Increase reinforcing efficacy of food/attention
- MO: increase value of escaping from demands

#### Resources

Van Haaren, F., & Weeded, M. (2013). Some guidelines for conducting research in applied behavioral pharmacology. *Journal* of Applied Behavior Analysis, 46, 498-506.

Julien, R.M., Advokat C.D., & Comaty, J.E. (2010). A primer of drug action, New York, Worth.

### **Resources Continued**

Schaal, D.W., & Hackenberg (1994) Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities, *American Journal on Mental Retardation, 99,* 123-140

### References available upon request

Thank you